Science & Technology
Novel peptide therapeutics to treat cystic fibrosis-related diabetes
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R42DK145320-01
Award Ceiling
$280K
Award Floor
$280K
Close Date
Jun 30, 2028
838 days leftTotal Funding
$280K
Expected Awards
1
Posted Date
Sep 12, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R42DK145320-01
Description
STTR Phase Phase I award: "Novel peptide therapeutics to treat cystic fibrosis-related diabetes" awarded to ELDEC PHARMACEUTICALS INC. in CHAPEL HILL, North Carolina. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $280,122. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.